Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

BioLineRx Ltd. (BLRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.8800-0.1600 (-5.26%)
At close: 4:00PM EDT
2.8800 0.00 (0.00%)
After hours: 07:18PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close3.0400
Open2.9800
Bid2.8800 x 800
Ask2.9300 x 1800
Day's Range2.8500 - 2.9800
52 Week Range1.4000 - 6.3400
Volume337,647
Avg. Volume421,578
Market Cap136.22M
Beta (5Y Monthly)1.45
PE Ratio (TTM)N/A
EPS (TTM)-1.0950
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BLRX

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BioLineRx Ltd.
    Analyst Report: Quest Diagnostics IncorporatedQuest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of nearly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
    Rating
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • PR Newswire

    BioLineRx Announces Positive Results from Pharmacoeconomic Study Positioning Motixafortide as Potential Standard of Care in Stem Cell Mobilization

    BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced positive results from a pharmacoeconomic study evaluating the cost-effectiveness of using investigational drug Motixafortide as a primary stem cell mobilization (SCM) agent on top of granulocyte colony stimulating factor (G-CSF), versus G-CSF alone, in multiple myeloma patients undergoing autologous stem cell transplantation (ASCT). The study was performed by the Globa

  • Insider Monkey

    11 Best Stocks for Long Term Growth

    In this article, we discuss the 11 best stocks for long-term growth. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Stocks for Long Term Growth. As the economy recovers post COVID-19, many investors see the surge in consumer spending and the expansion of the digital economy […]

  • PR Newswire

    BioLineRx Reports Second Quarter 2021 Financial Results and Provides Corporate Update

    BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended June 30, 2021 and provides a corporate update.

Advertisement
Advertisement